One-Page Truth-Telling Aid for Cancer Disclosure
A One-Page Truth-Telling Aid for Cancer Disclosure in Taiwan: A Two-Arm Pragmatic Randomized Controlled Trial
1 other identifier
interventional
400
1 country
1
Brief Summary
The goal of this clinical trial is to learn whether a one-page communication aid can improve communication between physicians and patients with cancer during cancer-related truth-telling consultations. The one-page aid is designed to help physicians quickly understand patients' preferences and needs before the consultation. The main questions it aims to answer are:
- Does the one-page communication aid improve patients' satisfaction with how cancer-related information is explained?
- Does the one-page communication aid reduce patients' emotional distress after the consultation?
- Does the one-page communication aid improve physicians' confidence in communicating cancer-related information? Researchers will compare patients whose physicians receive the one-page communication aid with patients whose physicians provide usual care with a blank sheet for patients to write down questions. This comparison will help determine whether the one-page aid improves communication, emotional outcomes, and physician confidence. Participants will:
- Complete questionnaires before and after the consultation
- Receive either the one-page communication aid or a blank sheet, depending on their physician's group
- Complete follow-up questionnaires at 3 months and 6 months after the consultation Physicians will also complete brief questionnaires about their communication confidence at baseline, 1 week after recruitment of their first enrolled patient, 3 months, and 6 months.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Nov 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 27, 2025
CompletedFirst Submitted
Initial submission to the registry
July 21, 2026
CompletedFirst Posted
Study publicly available on registry
July 28, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2027
July 28, 2026
July 1, 2026
1.3 years
July 21, 2026
July 22, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Patients' Truth-Telling Preferences and Perceptions
Patients' truth-telling preferences and perceptions of physicians' actual disclosure practices will be assessed using the 43-item Truth-Telling Questionnaire (TTQ-43). The TTQ-43 includes four domains: how to deliver bad news, emotional support, additional information, and setting. Items are scored from 1 to 5, with higher scores indicating stronger preferences expectation at baseline or greater perceived alignment with physician practice at follow-up.
Baseline, immediately after the truth-telling consultation, 3 months post-intervention, and 6 months post-intervention
Secondary Outcomes (8)
Patients' Psychological Distress
Baseline, immediately after the truth-telling consultation, 3 months post-intervention, and 6 months post-intervention
Physicians' Confidence in Communication
Baseline, 1 week after recruitment of the physician's first enrolled patient, 3 months post-intervention, and 6 months post-intervention
Patients' Decision Regret
3 months post-intervention and 6 months post-intervention
Treatment-Related Adverse Events
3 months post-intervention and 6 months post-intervention
Medical Expenditure
6 months post-intervention
- +3 more secondary outcomes
Study Arms (2)
One-Page Truth-Telling Aid
EXPERIMENTALPatients in this arm will receive the One-Page Truth-Telling Aid before the truth-telling consultation. The aid will be completed with the patient before the visit and summarizes the patient's disclosure preferences, communication needs, and questions for the physician. Patients will be encouraged to provide the aid to their participating physician at the beginning of the consultation so that the physician can quickly understand the patient's preferences and tailor communication accordingly.
Blank Sheet
ACTIVE COMPARATORPatients in this arm will receive a blank sheet before the truth-telling consultation. The blank sheet may be used to write down questions or concerns the patient would like to discuss with the physician. It does not include structured questions about disclosure preferences or communication needs. Patients will receive usual care and may choose whether to provide the blank sheet to their participating physician during the consultation.
Interventions
The One-Page Truth-Telling Aid is a brief communication aid completed with patients before the consultation. It summarizes patients' disclosure preferences, communication needs, and questions for the physician. Patients are encouraged to provide the aid to their participating physician at the beginning of the consultation to support patient-centered communication.
The blank sheet is provided to patients before the consultation and may be used to write down questions or concerns. It does not include structured questions about disclosure preferences or communication needs.
Eligibility Criteria
You may qualify if:
- Physicians who provide clinical care for patients with cancer in participating outpatient departments.
- Physicians who are involved in cancer-related truth-telling or disclosure consultations.
- Physicians who are willing to participate and provide informed consent.
You may not qualify if:
- Physicians who are unable or unwilling to complete study procedures or follow-up assessments.
- 【Patients】
- Patients diagnosed with cancer.
- Patients who are scheduled to receive cancer-related information from a participating physician, including information about diagnosis, recurrence, metastasis, end-of-life status.
- Patients who are able to communicate in Mandarin Chinese or Taiwanese.
- Patients who are able to complete questionnaires independently or with assistance from the research assistant.
- Patients who are willing to participate and provide informed consent.
- Patients who are unable to provide informed consent.
- Patients with severe cognitive impairment, severe physical illness, or emotional distress that prevents participation, as judged by the clinical team or research staff.
- Patients who are unable to complete the study questionnaires even with assistance.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Chang Gung Universitylead
- Chang Gung Memorial Hospitalcollaborator
Study Sites (1)
Chang Gung University
Taoyuan, 33302, Taiwan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Shih-Ying Chen, PhD
Chang Gung University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Masking Details
- Patients will be masked to group assignment. Both groups will receive a study sheet before the consultation to support preparation for the visit. Patients in the experimental group will receive the One-Page Truth-Telling Aid, whereas patients in the control group will receive a blank sheet. Physicians and the research assistant cannot be masked because they are involved in delivering information or using the assigned study materials and data collection.
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
July 21, 2026
First Posted
July 28, 2026
Study Start
November 27, 2025
Primary Completion (Estimated)
April 1, 2027
Study Completion (Estimated)
July 1, 2027
Last Updated
July 28, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will not share
Individual participant data will not be shared because the dataset contains sensitive clinical and communication-related information from patients with cancer and participating physicians. De-identified aggregate results may be reported in publications.